Université de Fribourg

The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model

Hagen, Timo L.M. ten ; Seynhaeve, Ann L.B. ; Wiel-Ambagtsheer, Gisela aan de ; Bruijn, Ernst A. de ; Tiel, Sandra T. van ; Rüegg, Curzio ; Meyring, Michael ; Grell, Matthias ; Goodman, Simon L. ; Eggermont, Alexander M.M.

In: International Journal of Cancer, 2012, p. -

Isolated limb perfusion (ILP) with melphalan and tumor necrosis factor (TNF)-α is used to treat bulky, locally advanced melanoma and sarcoma. However, TNF toxicity suggests a need for better-tolerated drugs. Cilengitide (EMD 121974), a novel cyclic inhibitor of alpha-V integrins, has both anti-angiogenic and direct anti-tumor effects and is a possible alternative to TNF in ILP. In this study,...